| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H17F3N2O4 |
| Molecular Weight | 406.3552 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC2=C1C(O)=C(C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)C(=O)N2C
InChI
InChIKey=ONDYALNGTUAJDX-UHFFFAOYSA-N
InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
| Molecular Formula | C20H17F3N2O4 |
| Molecular Weight | 406.3552 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Sourcing
Sample Use Guides
Tasquinimod is given orally at a dose of 1 mg once daily.
Route of Administration:
Oral
LNCaP prostate tumor cells were cultured with 50 uM of tasquinimod for 24 h to test its effect on gene expression. At 10 uM tasquinimod the TSP1 mRNA expression was elevated at 6 h and peaked after 72 h. Moreover, after 72 h exposure the TSP1 mRNA levels was already elevated at a dose of 1 uM tasquinimod.
